The autophagic regulation of rosiglitazone-promoted adipocyte browning

Front Pharmacol. 2024 Jun 4:15:1412520. doi: 10.3389/fphar.2024.1412520. eCollection 2024.

Abstract

Objective: Browning of white adipocytes is considered an efficient approach to combat obesity. Rosiglitazone induces the thermogenetic program of white adipocytes, but the underlying mechanisms remain elusive. Methods: Expression levels of browning and autophagy flux markers were detected by real-time PCR and immunoblotting. H&E and Oil Red O staining were performed to evaluate the lipid droplets area. Nuclear protein extraction and immunoprecipitation were used to detect the proteins interaction. Results: In this study, we reported that rosiglitazone promoted adipocyte browning and inhibited autophagy. Rapamycin, an autophagy inducer, reversed adipocyte browning induced by rosiglitazone. Autophagy inhibition by rosiglitazone does not prevent mitochondrial clearance, which was considered to promote adipose whitening. Instead, autophagy inhibition increased p62 nuclear translocation and stabilized the PPARγ-RXRα heterodimer, which is an essential transcription factor for adipocyte browning. We found that rosiglitazone activated NRF2 in mature adipocytes. Inhibition of NRF2 by ML385 reversed autophagy inhibition and the pro-browning effect of rosiglitazone. Conclusion: Our study linked autophagy inhibition with rosiglitazone-promoted browning of adipocytes and provided a mechanistic insight into the pharmacological effects of rosiglitazone.

Keywords: PPARγ agonist; adipocyte browning; autophagy; mitophagy; obesity; rosiglitazone.

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was funded by the National Natural Science Foundation of China (82373923 and 82173792), the Zhejiang Provincial Natural Science Foundation (LZ21H310001 and LYY22H310009), Jinhua Science and Technology Plan Projects (2023-3-170), the Starry Night Science Fund of Zhejiang University Shanghai Institute for Advanced Study (SN-ZJU-SIAS-0011), Chinese Pharmaceutical Association—Servier Youth Hospital Pharmaceutical Innovation Research Funding Project (CPA-B04-ZC-2023-001) and the Fundamental Research Funds for the Zhejiang Provincial Universities (226-2023-00013).